Beactica Therapeutics strengthens its preclinical development team
Beactica Therapeutics AB, the Swedish precision oncology company, today announced two appointments to its preclinical development team. Dr Anneli Hällgren will lead the preclinical development and Dr Carl Magnus Andersson will lead the CMC activities. The appointments are made in preparation for IND-enabling studies of preclinical candidate BEA‑17, a novel small molecule cancer immunotherapeutic agent under development by Beactica.Dr Anneli Hällgren has more than 25 years of experience from drug development within several therapeutic areas and with emphasis on preclinical development